• Latest Posts

The Billion-Euro European Biotech Companies in 2022

Delayed IPOs and Market Drops Batter Biotech Stocks

Galapagos and Gilead Soldier On After Inflammatory Disease Flops

A Year to Remember: The Biggest European Biotech News in 2020

Galapagos’ Arthritis Drug Approved in EU and Japan Amid US Rejection

MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II


Gilead Pays Billions for Access to Galapagos’ Pipeline

The 8 Best Biotech Companies in Europe’s History

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

Interview 23 Oct 2018

Bridging the Academia-Industry Divide: Lessons from a Serial Biotech Entrepreneur

Morphosys and Galapagos Announce Positive Phase I Results for Atopic Dermatitis Treatment